BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.

老虎证券2026/05/04 11:16

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions

Rothe Development, a contractor that provides engineering and mission operations services to NASA and other federal agencies, filed on Tuesday with the SEC to raise up to $50 million through an initial public offering (IPO).

智通财经•2026/09/09 08:11

Guna Timur Raya says no undisclosed material developments behind TRUK share rise

Reuters•2026/09/09 08:04

Jolt Capital leads investment in fleet electrification firm VEV

Reuters•2026/09/09 08:04

Santander launches USD 2 million 3-year equity-linked notes offering

Reuters•2026/09/09 08:03